Nasopharyngeal cancerGastric cancerColorectal cancerLiver cancerLung cancer
Established
1964
Beds
2,200+
Annual Volume
1,800,000+
Guangzhou
Global hub for nasopharyngeal cancer care and research; multiple studies have rewritten international guidelines.
About the Hospital
Sun Yat-sen University Cancer Center is the largest cancer specialty hospital in South China and a world leader in nasopharyngeal carcinoma (NPC) — Academician Ma Jun’s team has repeatedly rewritten international guidelines, raising NPC five-year survival to the best levels reported globally.
The center hosts the State Key Laboratory of Oncology in South China, with liver, lung, lymphoma and GI cancer programs all ranking nationally in both clinical volume and research output.
Hospital Strengths
01Global center for nasopharyngeal carcinoma
A complete system from screening and precise staging to induction chemotherapy and IMRT; its GP induction regimen for advanced NPC became an international standard.
02Liver cancer surgery and comprehensive care
The liver MDT is highly experienced in resection of large tumors, conversion therapy and combination strategies, with internationally low perioperative mortality.
03Clinical research and drug access
Annual registered-study volume ranks among the highest nationally, giving patients priority access to investigational agents.
01Precision radiotherapy and systemic therapy for NPC
02Liver cancer resection, ablation and conversion therapy
03Minimally invasive lung surgery and targeted/immuno-therapy
04Lymphoma care and CAR-T cell therapy
05MDT-based comprehensive GI cancer care
Officially Reported Treatment Milestones
Chinese regimen of enhanced efficacy and reduced toxicity for nasopharyngeal carcinoma
2016–2019
Academician Ma Jun’s team established induction chemotherapy plus concurrent chemoradiotherapy as the standard for nasopharyngeal carcinoma; results published in NEJM and other journals, repeatedly rewriting international guidelines.
Multidisciplinary comprehensive treatment of colorectal liver metastases
2012–
Established an MDT pathway for colorectal liver metastases combining surgery, interventional therapy, ablation and systemic treatment, giving some initially unresectable patients a chance at radical surgery.